Antiviral Research: At age 41, a transition

Abstract

This article marks the transition from Mike Bray to Subhash Vasudevan as editor-in-chief of Antiviral Research, in the journal's 41st year of publication. It reviews AVR's experience since 2011, when the founder and first editor-in-chief, Erik De Clercq, wrote a paper describing the journal's first 30 years. Since that time, the editorial team has doubled in size, with editors now located in 8 countries; half are women. There has been a corresponding increase in the number of published papers, covering research on antiviral drugs, vaccines and pathogenesis for a wide range of endemic and epidemic viral diseases of humans and livestock animals, and there has been a significant rise in the journal's impact factor. AVR's experience during the COVID-19 pandemic is also briefly summarized.